

# Index

- abortion, terminology of, 24  
 acceptance, 15  
 acquired activated protein C resistance (APCR), *See also* thrombophilia (acquired)  
   hypobaric hypoxia and, 146  
   recurrent implantation failure (RIF) and, 214  
   recurrent miscarriage (RM) and, 61–2, 121–2, 122–3  
 actinomycin D, 22  
 activin, 230  
 adhesion, 200–1  
 adnexal mass, ultrasound detection of, 50  
 adrenal gland, 175  
 age (parental)  
   as ectopic pregnancy risk factor, 19  
   as miscarriage risk factor, 101353  
   parental chromosome screening strategies and, 97  
 air travel, *See* travel-related venous thromboembolism (VTE)  
 alcohol intake, 111259222  
 allogeneic leukocyte immunization therapy (ALT), 152157  
   Cochrane analysis criticisms, 154  
   current controversy about, 151  
   negative aspects of, 156  
   possible action mechanisms in recurrent miscarriage (RM), 154, 157  
   trial heterogeneity, 152–4  
 American Fertility Society (AFS) uterine anomaly classification, 29 3233  
 amniocentesis, 248  
 amnion  
   empty, 46  
   visualization of, 41  
 amnion rupture sequence (ARS), 107  
 amnionity, multiple gestation assessment, 43–4  
 androgen levels, 175  
 anembryonic pregnancy/miscarriage, 344660  
 anemia, 68  
 anencephaly, 49  
 aneuploidy, *See* chromosomal/cytogenetic abnormality  
 antidiolipin (aCL) antibodies  
   antiphospholipid syndrome (APS) and pregnancy, *See*  
   antiphospholipid syndrome (APS)  
   antiphospholipid syndrome (APS) diagnostic criteria, 61114115  
   prevalence of, 115–16  
 anti-Müllerian hormone (AMH), 241  
 antinuclear antibody (ANA), 119  
 antibiotic therapy, 279  
 antiphospholipid syndrome (APS), 61120, *See also* thrombophilia (acquired)  
   clinical manifestations of antiphospholipid antibodies (aPL), 114  
   diagnostic criteria, 115  
   future pregnancy management, 123–4  
   late pregnancy loss (LPL) and, 277–8  
   markers of, 122–3  
   mechanism of pregnancy loss in, 116  
   pregnancy outcome in untreated, 116  
   prevalence of, 115–16  
   recurrent implantation failure (RIF) and, 120219  
   screening for, 114–15  
   steroid therapy and, 220  
   treatment in pregnancy, 116–20  
 antithrombin, 131  
 antithrombin deficiency, 62136138214, *See also* thrombophilia (inherited)  
   different forms of pregnancy loss and, 134  
   incidence of first venous thromboembolism, 133  
 anti-TNF- $\alpha$  agents, 81220  
 anti- $\beta_2$  glycoprotein-I antibody, 61 115  
 aPL antibodies, *See* antidiolipin antibodies (aCL); lupus anticoagulant (LA)  
 appendix rupture, ectopic pregnancy and previous, 20  
 apposition, 200  
 arcuate uterus, 29323334, *See also* congenital uterine anomalies  
 arg-gly-asp (RGD), 181  
 aromatase inhibitors, 184217220  
 ascorbic acid (AA), 217220  
 Ashermans syndrome, 180  
 aspirin  
   adjuvant therapy in IVF, 217219223  
   antiphospholipid syndrome (APS) treatment, 117–19, 123–4, 233278  
   inherited thrombophilia treatment, 137–8  
   travel-related VTE prevention, 147148  
   unexplained recurrent miscarriage (RM) and, 124  
 assisted hatching, 216239  
 Association of Early Pregnancy Units (AEPU), mission statement, 1  
 bacterial vaginosis (BV), 219279  
 Beckwith–Wiedemann syndrome, 72  
 bereavement counseling, 4  
 bicornuate uterus, 29323334, *See also* congenital uterine anomalies  
 biochemical pregnancy loss, 5  
   classification of, 560  
 birth weight, low, 269271–2  
 bisphenol A, 59  
 blame, 15  
 blastocyst  
   features associated with implantation, 204  
   pre-implantation, 199–200  
 blastocyst transfer, 239  
 BMI (body mass index), miscarriage risk and, 12  
 bowel herniation, embryonic development, 4349107  
 bradycardia, embryonic, 47–8  
 butterfly sign, 49  
 cadherins, 182  
 caffeine, 111259222259  
 cell adhesion molecules (CAMs), 181–2, 184  
   integrins, *See* integrins  
 centric fusion/Robertsonian translocation, 94255  
 cerebral palsy, 251–2, 269272279  
 cervical cerclage  
   transabdominal (TAC), 281–5  
   transvaginal, 280–1, 284

## Index

- cervical length, pre-term delivery risk and, 247
- cervical weakness  
   late pregnancy loss (LPL) and, 278–9  
   management by cervical cerclage, 280–5
- chlamydia trachomatis, 19
- chorangiopagus parasiticus (CAPP), 107
- choriocarcinoma, 6771
- chorion biopsy, direct, 105109
- chorionic bump, 47
- chorionic villous sampling (CVS), 248
- chorionicity, multiple gestation assessment, 43–4
- chromosomal/cytogenetic abnormality  
   carrier status and pregnancy outcome, 98–9  
   carrier status probability, 98  
   causative errors in meiosis, 86–7  
   cytogenetic evaluation of conceptus, 105109–10  
   embryo reduction (ER) and diagnosis, 247248  
   errors in meiosis, 92–5  
   implantation failure and, 215–16, 237  
   incidence at different reproductive/developmental stages, 86  
   karyotype and embryonic morphology correlation, 108  
   miscarriage and, 9–10, 5385–7  
   miscarriage tissue analysis, *See* miscarriage tissue analysis  
   mosaicism, 95216232  
   normal process of meiosis, 85–6  
   ovarian stimulation and, 215–16  
   parental chromosome testing, *See* parental chromosome testing  
   post-IVF miscarriage and, 256–8  
   pre-implantation genetic screening (PGS), *See* pre-implantation genetic screening (PGS)  
   prenatal diagnosis (PND), 99248  
   trophoblasts and, 232  
   uterine natural killer (uNK) cells and, 80  
   vanishing twin syndrome and, 268
- cleavage, early, 238–9
- cleft lip, 107
- cleft palate, 107
- clindamycin, 279
- clomiphene citrate, 220
- coagulation system  
   changes in pregnancy, 144  
   regulation of, 131
- cobalamin, 222
- colony stimulating factor-1 (CSF-1), 7579230
- communication, standards in, 4
- comparative genomic hybridization (CGH), 95–7, 277
- with flow cytometry (CGH/FCM), 87
- complement, 116208
- complete hydatidiform mole (CHM), 367–70
- compression stockings, travel-related VTE prevention, 147
- conceptual age, terminology of, 3
- Confidential Inquiry into Maternal Deaths (2007), 2
- confined placental mosaicism (CPM), 232
- congenital uterine anomalies  
   classification of, 293233  
   formation mechanism, 29  
   in early pregnancy, 34–5  
   late pregnancy loss (LPL) and, 279–80  
   magnetic resonance imaging (MRI) diagnosis, 33  
   post-IVF miscarriage and, 261  
   reproductive performance and, 33–4, 61  
   three-dimensional transvaginal ultrasound diagnosis, 32–3  
   two-dimensional transabdominal ultrasound diagnosis, 29–30  
   two-dimensional transvaginal ultrasound diagnosis, 30–2
- cornual pregnancy, 34–5
- corpus luteum (CL), 50175
- crown–rump length (CRL)  
   measurement, 4043103
- culture models, endometrial receptivity and, 166–7
- cumulus cells, 241
- curettage, miscarriage management, 56–7
- cyclooxygenase, 117–18, 202207219
- cystic hygroma, 49
- cytogenetic abnormality, *See* chromosomal/cytogenetic abnormality
- cytokines  
   endometrial assessment, 182–3  
   increased production and recurrent implantation failure (RIF), 184  
   interleukins, *See* interleukins  
   natural killer (NK) cells and, 76  
   uNK cells and, 7578–9  
   vascular remodeling and, 79
- cytoplasmic transfer, 240
- danazol, 184
- D-dimers, 144145
- decay accelerating factor (DAF), 182
- dermoid cyst, 50
- DHEA-S (dehydroepiandrosterone-sulfate), 175
- diabetes, 60260
- diamond ring sign, 41
- didelphic uterus, 29 *See also* congenital uterine anomalies
- diet  
   IVF outcome and, 222  
   miscarriage risk and, 1112
- diethylstilbestrol (DES), 2055
- dilute Russell's Viper Venom Time (dRVVT), 115
- DNA microarray analysis, 164–5, 172183185
- donor lymphocyte transfusions (DLT), *See* allogeneic leukocyte immunization therapy (ALT)
- double bleb sign, 43
- double decidual sac sign (DDSS), 3940
- Down's syndrome, 49247
- duplication abnormalities, embryonic, 107
- early embryonic demise, 3446, *See also* empty sac diagnosis
- early pregnancy assessment units (EPU)  
   models of care and, 1  
   site of, 4
- early pregnancy loss. *See* miscarriage
- eclampsia, 231
- ectopic pregnancy  
   changes in presentation of, 19  
   diagnosis of, 19–20, 55  
   expectant management, 24  
   intrauterine pregnancy in anomalous uterus differential diagnosis, 34–5  
   medical management, 22–3  
   risk factors for, 19  
   ruptured, 48  
   standardized reporting of, 2  
   subsequent fertility, 24–5  
   surgical management, 20–2  
   types of, 19
- embryo  
   quality assessment of, 237–9, 240–1  
   terminology of, 3105
- embryo biopsy, 88
- embryo loss, 4 *See also* empty sac diagnosis
- embryo reduction (ER)  
   indications and justifications for, 245–6  
   outcome after, 245248–52  
   spontaneous, *See* vanishing twin syndrome  
   technical and practical aspects of, 246–8
- embryo transfer (ET), 217218–19
- embryonic age, terminology of, 3
- embryonic bradycardia, 47–8
- embryonic death, terminology and definition of, 3

- embryonic development  
 abnormal first-trimester ultrasound findings, 44–6  
 defects in, 105–8, 109–10  
 embryoscopic detection of defects, *See* embryoscopy  
 normal first-trimester ultrasound findings, 41–3  
 embryonic growth disorganization, 106108110  
 embryonic miscarriage, classification of, 60  
 embryonic period, terminology of, 4  
 embryoscopy  
 advantages of, 103109–10  
 embryonic malformations, 105–8  
 indications for, 109  
 transcervical technique, 103–5  
 emotional response, to miscarriage, 114–15  
 emotional wellbeing, 1116  
 empty sac diagnosis, 2–4, 60, *See also* anembryonic pregnancy/  
 miscarriage  
 encephalocele, 106  
 endocrinopathy, 175260  
 endometrial assessment  
 clinical perspective of, 183–5  
 diagnostic dilemmas and, 185  
 endometrial biopsy, 173–5, 183216  
 endometrial receptivity biomarkers, 180–3  
 future directions, 185–6  
 histology, 173–5  
 historical perspective, 171–2  
 hormonal, 175–6  
 imaging, 177–80  
 secretion analysis, 215  
 ultrastructure, 176–7  
 endometrial co-culture systems, 216  
 endometrial granulocytes, *See* uterine natural killer (uNK) cells  
 endometrial receptivity  
 background information, 161  
 defects in, 173  
 endometrial assessment, *See* endometrial assessment  
 endometrial gene expression profile regulation, 162–3, 215  
 future study direction, 167  
 global process of, 165–6  
 histological endometrial features along menstrual cycle, 161–2  
 markers of, 163–5, 172176–7, 180–3  
 new study methods, 166–7  
 ovarian stimulation regimen and, 216–18  
 post-IVF miscarriage and, 260–1  
 recurrent implantation failure (RIF) and, 215  
 study summary, 164  
 uterine vasodilatation and, 219–20  
 window of implantation (WOI), 161167171–3, 176  
 endometrial receptivity array (ERA), 166  
 endometrial thickness, 177–9, 215  
 endometrioma, 50180  
 endometriosis  
 diagnostic and treatment dilemmas, 183–4  
 endometrial receptivity and, 173  
 nucleolar channel systems (NCSs) and, 177  
 recurrent implantation failure (RIF) and, 184  
 recurrent miscarriage (RM) and, 185  
 enoxaparin, 137  
 epidermal growth factors (EGF), 181182205  
 epidural bleeding, 136  
 erythromycin, 279283  
 estradiol  
 endometrial assessment, 175  
 levels in menstrual cycle, 162  
 synthesis reduction, 220  
 estrogen  
 as implantation mediator, 202–4  
 synthesis reduction, 220  
 estrogen receptors (ER), 162175202–4  
 exencephaly, 49  
 exercise, physical, 11259  
 expected date of delivery (EDD), ultrasound confirmation, 39–43  
 extravillous trophoblast (EVT) cells, 78–9  
 facial dysplasia, 107  
 factor V Leiden mutation, 61–2, 113121, *See also* thrombophilia (inherited)  
 association with different forms of pregnancy loss, 134135  
 incidence of first venous thromboembolism, 133  
 pre-conceptual cervical cerclage, 284  
 pregnancy outcome trials, 137–8, prevalence of, 121132  
 recurrent implantation failure (RIF) and, 214  
 travel-related venous thromboembolism and, 143146  
 factor VIII, elevated, 133134, *See also* thrombophilia (inherited)  
 fetal anomalies, ultrasound findings, 49–50, 54–5  
 fetal loss, terminology of, 3  
 fetal miscarriage, classification of, 60  
 fetal period, terminology of, 4  
 fetus, terminology and definition of, 34105  
 fibrinogen, 144  
 fibroblast growth factor, 202  
 fibroids, 3350213–14, 261  
 flow cytometry, with comparative genomic hybridization (CGH/FCM), 87  
 fluorescent in situ hybridization (FISH) analysis, 868895216257  
 folate deficiency, 63  
 folic acid, 12222  
 follicle stimulating hormone (FSH)  
 endometrial assessment, 175  
 ovarian stimulation use, 217218256–7  
 follicular fluid assessment, 241  
 gastroschisis, 118  
 gene expression markers, endometrial receptivity, 164–5  
 genetic investigations and screening  
 miscarriage tissue analysis, *See* miscarriage tissue analysis  
 molar pregnancy, 71  
 parental chromosome testing, *See* parental chromosome testing  
 pre-implantation, *See* pre-implantation genetic screening (PGS)  
 recurrent miscarriage (RM), 60–1  
 genital infections, ectopic pregnancy and, 20  
 gestational age  
 pregnancy loss classification and, 5  
 terminology of, 2–4  
 gestational sac  
 abnormal ultrasound findings, 4654–5  
 expelled, 54  
 gestational trophoblastic disorders (GTD), 67  
 choriocarcinoma, 6771  
 first-trimester ultrasound findings, 48  
 gestational trophoblastic neoplasia (GTN), 67  
 molar pregnancy, *See* molar pregnancy  
 persistent gestational trophoblastic disease (pGTD), 707172  
 terminology, 35  
 gestational trophoblastic neoplasia (GTN), 67  
 Giemsa banding analysis, 87  
 glycocalyx, 176  
 glycodeilin, endometrial secretion levels, 215  
 GnRH agonists, 184217256–7  
 GnRH analogs, 184  
 GnRH antagonists, 175218256–7  
 gonadotropin, 175

## Index

- granular endometrial stromal cell, *See* uterine natural killer (uNK) cells
- granulocyte colony stimulating factor (G-CSF), 241
- granulocyte-macrophage colony stimulating factor (GM-CSF), 7579
- granulysin, 79
- growth factors
- epidermal (EGF), 181182205
  - fibroblast, 202
  - hepatocyte, 202
  - implantation mediation, 205–6
  - insulin-like (IGF), *See* Ind325
  - transforming growth factor-beta (TGF- $\beta$ ), 7579230
  - trophoblast control, 230
  - uterine natural killer (uNK) cell secretion, 79
  - vascular endothelial (VEGF), 205–6
- guilt, after miscarriage, 15
- hCG (human chorionic gonadotrophin)
- blood levels, *See* hCG levels
  - ovarian stimulation use, 218
- hCG levels
- in ectopic pregnancy, 22232455
  - in molar pregnancy, 68697071
  - miscarriage classification, 60
  - molar pregnancy and, 67
  - quantitative beta, 44
  - standards in measurement of, 4
- head defects, embryonic, 106–7
- heart rate, embryonic, 47–8
- hemoperitoneum, 23
- heparin
- antiphospholipid syndrome (APS) use, 116–17, 118–19, 123–4, 233, 278
  - inherited thrombophilia use, 135–8
  - travel-related VTE prevention, 147148
  - unexplained recurrent miscarriage (RM) and, 124
  - use in IVF, 219
- hepatocyte growth factor, 202
- heterotopic pregnancy, 35
- histological dating, endometrial receptivity, 163173–5
- holoprosencephaly, 49
- hormone replacement therapy, 145
- HOX genes, 184206–7
- human chorionic gonadotrophin (hCG), *See* hCG (human chorionic gonadotrophin); hCG levels
- human leucocyte antigens (HLA), 207
- hydatidiform mole pregnancy, *See* molar pregnancy
- hydrosalpinx, 173180213259–60
- hyperandrogenism, 175179
- hyperemesis, 68
- hyperhomocysteinemia, 62–3, 120–1, 132, *See also* thrombophilia (acquired)
- different forms of pregnancy loss and, 134
  - first VTE incidence, 133
- hyperinsulinemia, 175
- hyperosmolar glucose, 22
- hyperprolactinemia, 60175260
- hyperthyroidism, 70
- hypobaric hypoxia, 146
- hypothalamic–pituitary–ovarian axis, 203
- hypothyroidism, 260
- hysterosalpingography (HSG), 29–30, 260280
- hysteroscopy, 280
- immunoglobulin, intravenous, *See* intravenous immunoglobulin (IVIG)
- immunohistochemical markers, endometrial receptivity, 164
- immunosuppression, 62207–8, 232
- immunotherapy
- allogeneic leukocyte immunization therapy (ALT), 152–4, 156157
  - background information, 151–2
  - current controversy about, 151
  - future directions, 157–8
  - in IVF, 220–1
  - intravenous immunoglobulin (IVIG), *See* intravenous immunoglobulin (IVIG)
  - negative aspects of, 156–7
  - possible action mechanisms in recurrent miscarriage (RM), 154157
  - uterine natural killer (uNK) cells and, 8182
- implantation
- biological processes required for, 199–202
  - endometrial receptivity and, *See* endometrial assessment; endometrial receptivity
  - in vitro fertilization rates, 213
  - invasion process, *See* trophoblast invasion
  - late pregnancy complications and, 208
  - molecular mediators of, 202–8
  - optimization in IVF summary, 217
  - overview of, 227–8
  - study of, 199227
  - window of (WOI), 161167
  - 171–3, 176
- implantation failure
- embryological features affecting, 237–9
- embryological strategies to overcome, 239–40
- endometrial receptivity and, *See* endometrial assessment; endometrial receptivity
- new techniques for oocyte/embryo quality assessment, 240–1
- recurrent, *See* recurrent implantation failure (RIF)
- timing of implantation and, 171–2
- in vitro fertilization (IVF), 270
- adjuvant medical therapies, 219–21, 222
- adverse singleton outcome, 267273
- assessment prior to, 221
- chromosome abnormality and subsequent miscarriage, 256–8
- embryo implantation optimization summary, 217
- embryo reduction (ER) after, *See* embryo reduction (ER)
- embryo transfer (ET) technique, 218–19
- endometrial receptivity and, 171173
- euploid miscarriage after, 258–9
- general management of subsequent miscarriage, 255–6
- implantation and endometrial defects in, 184
- lifestyle factors, 222
- miscarriage risk factors after, 259–61
- ovarian stimulation regimen, 216–18, 222256–7, 273
- policy on embryo transfer numbers, 273
- pre-implantation genetic screening (PGS) and, *See* pre-implantation genetic screening (PGS)
- recurrent implantation failure (RIF), *See* recurrent implantation failure (RIF)
- steroid use in, 81
- success/failure rates, 213
- industrial hazards, 59
- infertility
- endometrial assessment in unexplained, 183–4
  - subsequent miscarriage risk, 10–11, 13
- insulin levels, 175
- insulin sensitizing drugs, 217
- insulin-like growth factors (IGF), 205, 230
- integrins, 176181–2, 184204–5
- interferon-gamma (IFN- $\gamma$ ), 7579
- interleukins
- interleukin- (IL-), 207
  - interleukin- (IL-), 182
  - interleukin- (IL-), 77
  - interleukin- (IL-), 6275
- interstitial pregnancy, 34–5

- intradecidual sac sign (IDSS), 40  
 intraperitoneal hemorrhage,  
   ultrasound findings, 48  
 intrauterine adhesions, 180  
 intrauterine contraceptive device  
   (IUCD) use, 20  
 intrauterine growth restriction (IUGR),  
   208229  
 intrauterine plus ectopic pregnancy, 3  
 intravenous immunoglobulin (IVIG)  
   recurrent implantation failure (RIF)  
     and, 81220  
   recurrent miscarriage (RM) and,  
     120151154–8
- K cells, *See* uterine natural killer (uNK)  
 cells
- karyotyping, of pregnancy losses, *See*  
 miscarriage tissue analysis
- Klinefelters syndrome, 10
- lambda sign, 43
- laparoscopy  
   ectopic pregnancy diagnosis, 19  
   ectopic pregnancy management, 20–2
- laparotomy  
   ectopic pregnancy diagnosis, 19  
   ectopic pregnancy management, 20–1
- large granulated lymphocyte, *See*  
 uterine natural killer (uNK) cells
- last menstrual period (LMP),  
   terminology difficulties, 2
- late pregnancy  
   implantation defects and  
     complications in, 208  
   miscarriage in, *See* late pregnancy  
     loss (LPL)
- late pregnancy loss (LPL)  
   definition/classification of, 35277  
   diagnosis, 277  
   factors associated with, 277–80  
   investigation protocol, 277  
   management, 280–5  
   leukemia inhibitory factor (LIF),  
     75182206
- leukomalacia, 252
- lifestyle issues, 259
- limb malformations, 49107
- Lupron, 184
- lupus anticoagulant (LA)  
   acquired activated protein C  
     resistance (APCR) and, 121  
   antiphospholipid syndrome (APS)  
     and pregnancy, *See*  
       antiphospholipid syndrome (APS)
- antiphospholipid syndrome (APS)  
   diagnostic criteria, 61115
- antiphospholipid syndrome (APS)  
   screening, 115  
   prevalence of, 115–16
- recurrent implantation failure (RIF)  
   and, 120215
- luteal phase defect/deficiency (LPD),  
   60171  
   hormonal assessment, 175  
   incidence of, 173–5
- luteal phase supplementation, 217
- luteinizing hormone (LH), 175  
   hypersecretion of, 60
- lymphocytes, maternal, 207–8
- macrophage inflammatory protein- $\beta$   
   (MIP- $\beta$ ), 77
- macrophage migration inhibitory  
   factor (MIF), 79
- magnetic resonance imaging (MRI)  
   congenital uterine anomaly  
     detection/diagnosis, 33280  
   endometrial assessment, 179
- major histocompatibility complex  
   (MHC), 207
- male-specific minor histocompatibility  
   (HY) antigens, 151
- mannose-binding lectin (MBL), 62151
- matrix metalloproteinases (MMPs),  
   79206
- mean sac diameter (MSD)  
   measurement, 4043
- MECA-, 182
- media issues, 15
- meiosis  
   errors in, 86–7  
   process of, 85–6
- menstrual abortion, terminology of, 3
- menstrual age, terminology of, 3
- menstrual cycle, histological  
   endometrial features in, 161–2
- menstruation regulation, 77–8
- mesenchymal dysplasia, 72
- metabolomic analysis, of embryo, 240
- methotrexate, ectopic pregnancy  
   management, 22–3, 24–5
- methylene tetrahydrofolate reductase  
   (MTHFR), 113120
- metronidazole, 279
- microcephaly, 107
- mifepristone, 222356
- miscarriage  
   chromosomal/cytogenetic  
     abnormality and, 85–7  
   classification of, 2–6, 59  
   congenital uterine anomalies and,  
     33–4  
   definition of, 9  
   delayed, 3  
   diagnostic management, 54–5  
   early pregnancy failure ultrasound  
     findings, 44–7  
   early pregnancy loss definition, 35  
   ectopic pregnancy and previous, 20
- emotional response, 14–15
- epidemiology of, 53
- expectant management, 54
- failure of transformation of spiral  
   arteries and, 229
- future research directions, 56
- incomplete, 5456
- late, *See* late pregnancy loss (LPL)
- management of post-IVF  
   miscarriage, 258–9
- natural course and clinical findings  
   of, 53–4
- patient information and support,  
   13–16
- post-embryo reduction (ER),  
   245248–51
- pre-clinical, 35385
- premature placental exposure to  
   maternal blood, 230
- prevalence of, 953
- prevention of, 55–6
- recurrent, *See* recurrent miscarriage  
   (RM)
- risk factors after IVF, 259–61
- risk factors for, 9–14
- terminology of, 3
- therapeutic management, 56–7
- miscarriage tissue analysis, 60–1, 87–8,  
   255
- late pregnancy loss, 277
- terminology in, 105
- transcervical embryoscopy sampling,  
   105
- misoprostol, 56–7
- missed abortion, terminology of, 3
- MIST trial, 56
- models of care  
   current standards in, 16–4  
   early pregnancy change  
     classification, 24–5  
   evolution of, 1–2  
   future direction of, 5–6
- molar pregnancy, 367–8  
   complete hydatidiform mole  
     (CHM), 67–70  
   partial hydatidiform mole (PHM),  
     67–8, 6970–2  
   pseudo-molar pregnancies, 72
- monosomy, *See* chromosomal/  
   cytogenetic abnormality
- morula, 199
- MRI, *See* magnetic resonance imaging  
   (MRI)
- mucins, 176
- multiple pregnancies  
   embryo reduction in, *See* embryo  
     reduction (ER)  
   increasing incidence of, 245  
   ultrasound first-trimester findings,  
     43–4



## Index

- multiplex ligation-dependent probe amplification (MLPA), 95  
 National Women's Health Study (NWHs), miscarriage risk factor findings, 9–13  
 natural killer (NK) cells  
   implantation and, 207  
   peripheral blood, 6275–6, 7780–1  
   recurrent implantation failure (RIF) and, 184  
   uterine, *See* uterine natural killer (uNK) cells  
 nausea, miscarriage risk and, 13  
 neisseria gonorrhoeae, 19  
 nitric oxide donors, 217219–20  
 nomenclature revision, 1–6, 59  
 NSAIDs (non-steroidal anti-inflammatory drugs), 117–18  
 nucleolar channel systems (NCSs), 177  
 nucleolar precursor bodies (NPB), 238  
 obesity  
   endometrial assessment, 175  
   miscarriage risk and, 1259259  
   recurrent implantation failure (RIF) and, 221–2  
 occupational hazards, 1159  
 omphalocele, 107  
 oocyte, assessment of, 239240–1  
 oral contraceptive pill, 132–3, 145146  
 osteopontin, 164182  
 osteoporosis, 119  
 ovarian lesions, 50  
 ovarian stimulation, 216–18, 220  
   222, 273  
   chromosome abnormality and, 215–16, 256–7  
   hyperstimulation, 50222  
 ovarian torsion, 3968  
 oxygen tension, implantation and, 202  
 pain  
   causes of pelvic pain, 50  
   during miscarriage, 54  
 parental chromosome testing, 60  
   background information, 91–2  
   biological basis of chromosomal abnormality, 92–5  
   carrier status and pregnancy outcome, 98–9  
   carrier status probability, 98  
   chromosome study techniques, 95–7  
   counseling and therapeutic options, 99–100  
   future directions, 101  
   screening strategies, 97–8  
 partial hydatidiform mole (PHM), 367–8, 6970–2  
 partner lymphocyte therapy (PLT), *See* allogeneic leukocyte immunization therapy (ALT)  
 patient choice, standards in, 4  
 patient information and support, standards in, 4  
 pelvic inflammatory disease, 56  
 perigestational hemorrhage (PGH), 48  
 peroxisome proliferator-activated receptor- $\delta$  (PPAR $\delta$ ), 207  
 persistent gestational trophoblastic disease (pGTD), 707172  
 phagocytosis, necrotized trophoblast, 232  
 pinopodes, 163–4, 176–7, 184200  
 pituitary gland, 175  
 placenta accreta, 231  
 placenta previa, 48219  
 placental abruption, 48  
 placental trophotropism, 48  
 placentation, 227  
   consequences of premature exposure to maternal blood, 230  
   early ultrasound findings, 43  
   exposure to maternal blood, 229  
   late pregnancy complications and, 208  
   study of, 230  
   trophoblast biology and, *See* trophoblasts  
 plasminogen activator inhibitor 2 (PAI 2), 144  
 polycystic ovary syndrome (PCOS), 6068175220260  
 post-ovulatory age, terminology of, 3  
 potassium chloride, 2223  
 pre-clinical embryo loss, terminology of, 35  
 prednisolone, 8081220  
 prednisone, 117151  
 pre-eclampsia  
   detection of, 229  
   failed transformation of spiral arteries and, 229–30  
   implantation defects and, 208  
   in molar pregnancy, 6870  
   trophoblast deportation, 231  
 pregnancy associated placental protein A (PAPP-A), 232  
 pregnancy duration  
   standardized reporting, 2–4  
   terminology of, 3  
 pregnancy loss, *See* miscarriage;  
   recurrent miscarriage (RM)  
 pregnancy of unknown location (PUL), 3555  
   ectopic pregnancy and, 20  
   pregnancy success prediction, 56  
   63–3  
 pre-implantation genetic screening (PGS), 256–8  
   early pregnancy loss risk and, 55–6  
   in recurrent implantation failure (RIF), 215–16, 237  
   in recurrent miscarriage (RM), 8688–9, 99–100  
 pre-term delivery  
   after cervical cerclage, 280–1, 282–4  
   cervical length and risk of, 247  
   cervical weakness and, 279  
   molar pregnancy, 70  
   vanishing twin syndrome and, 271  
 progesterone  
   early pregnancy levels, 44  
   ectopic pregnancy management and levels of, 23  
   endometrial assessment and, 175–6  
   implantation mediation, 202–4  
   IVF use, 217  
   menstrual cycle levels, 162  
   mid-luteal phase levels and recurrent miscarriage (RM), 60  
   miscarriage prevention, 55  
   pregnancy viability assessment and levels of, 55  
   uterine natural killer (uNK) cell regulation, 77  
 progesterone receptors (PR), 163175202–4  
 progesterone resistance, 176184  
 prolactin, 175  
 prostaglandins, 22207  
 protein C, 131  
   acquired resistance, *See* acquired activated protein C resistance (APCR)  
 protein C deficiency, 62138214 *See also* thrombophilia (inherited)  
   different forms of pregnancy loss and, 134  
   incidence of first venous thromboembolism, 133  
 protein S, 131  
 protein S deficiency, 62137138214 *See also* thrombophilia (inherited)  
   different forms of pregnancy loss and, 134  
   first VTE incidence, 133  
 proteomic analysis, 240  
 prothrombin mutation, 61–2, 113132, *See also* thrombophilia (inherited)  
   different forms of pregnancy loss and, 134  
   incidence of first venous thromboembolism, 133  
 pseudo-molar pregnancies, 72

- quantitative PCR (QF-PCR), 95
- recurrent implantation failure (RIF)  
 antiphospholipid syndrome (APS)  
 and, 120  
 clinical approach to, 216–21  
 diagnostic criteria, 213  
 embryo factors in, 215–16  
 endometrial defects and in vitro  
 fertilization (IVF), 184  
 lifestyle factors in, 221–2  
 maternal factors in, 213–15  
 summary of current issues, 222–3  
 uterine natural killer (uNK) cells  
 and, 81
- recurrent miscarriage (RM)  
 anatomical abnormality detection, 61  
 chromosomal/cytogenetic  
 abnormality and, 85–9  
 congenital uterine anomalies and,  
 33–4, 280  
 definition of, 397  
 endocrinological investigations,  
 59–60  
 endometrial defects and, 184–5  
 history-taking, 59  
 human leukocyte antigen (HLA)  
 testing, 63  
 hyperhomocysteinemia  
 investigation, 62–3  
 idiopathic, 6388  
 immunologic investigations, 62  
 immunotherapy for, *See*  
 immunotherapy; *specific therapies*  
 infective screen, 59  
 investigations following, 1559–63  
 miscarriage classification, 59  
 miscarriage tissue analysis, 87–8  
 natural killer cells and, 79–81  
 parental chromosome testing, *See*  
 parental chromosome testing  
 pregnancy loss classification and, 5  
 pre-implantation genetic screening  
 (PGS) and, 88–9  
 subsequent miscarriage risk  
 following, 10–11  
 subsequent pregnancy support, 15  
 supportive care in unexplained, 124  
 thrombophilia and, *See*  
 thrombophilia (acquired);  
 thrombophilia (inherited)  
 thrombophilia testing, 61–2  
 variation in reported cause  
 statistics, 113
- reporting standards, nomenclature  
 revision and, 1–6
- reproductive history (maternal),  
 miscarriage risk and, 10–11, 13
- retained products of conception  
 (RPOC), 46–7
- risk  
 communication of, 13–14, 15  
 concept of, 13  
 coping with, 15–16  
 Robertsonian translocation, 94255
- salpingectomy  
 ectopic pregnancy management,  
 20–2, 24–5  
 hydrosalpinx management, 213
- salpingostomy, ectopic pregnancy  
 management, 20–2, 24–5
- selectins, 182
- septate uterus, 293361180261, *See also*  
 congenital uterine anomalies  
 service availability, standards in, 4
- sex chromosomal mosaicism, 95
- skewed X-chromosome inactivation  
 (XCI), 97
- small-for-gestational age (SGA), 271
- smoking  
 as ectopic pregnancy risk factor,  
 1920  
 history in recurrent miscarriage  
 (RM), 59  
 infertility and, 221  
 miscarriage risk and, 1112  
 socio-economic status, miscarriage risk  
 and, 11
- sonohysterography, 179–80
- Special Interest Group for Early  
 Pregnancy (SIGEP), 59
- spina bifida, 107
- spiral arteries  
 consequences of failed  
 transformation, 229–30  
 transformation of, 228–9  
 trophoblast plug formation, 229
- spontaneous reduction, *See* vanishing  
 twin syndrome
- steroid therapy  
 antiphospholipid syndrome (APS)  
 and, 117  
 in IVF, 217220–1, 223  
 pre-conceptual, 8081  
 prophylactic antenatal, 282
- stress  
 dealing with, 16  
 miscarriage risk and, 11  
 12–13, 16
- subseptate uterus, 29323334, *See also*  
 congenital uterine anomalies
- syncytial knots, 231–2
- syncytiotrophoblast, 227
- syndactyly, 107
- synechiae, intrauterine, 261280
- teratoma, benign ovarian, 50
- termination of pregnancy  
 congenital uterine anomalies  
 and, 35  
 ectopic pregnancy and previous, 20  
 miscarriage risk after previous, 11  
 molar pregnancy, 70  
 terminology of, 3
- testosterone, 175
- theca lutein cysts, 4850686970
- thrombin, 131
- thrombin-antithrombin (TAT)  
 complexes, 122144
- thromboelastogram (TEG) testing,  
 122–3
- thrombophilia (acquired)  
 acquired activated protein C  
 resistance (APCR), *See* acquired  
 activated protein C resistance  
 (APCR)  
 antiphospholipid syndrome (APS),  
*See* antiphospholipid syndrome  
 (APS)  
 future pregnancy management,  
 123–4  
 global markers of, 122–3  
 hyperhomocysteinemia, *See*  
 hyperhomocysteinemia  
 recurrent implantation failure (RIF)  
 and, 214–15  
 recurrent miscarriage (RM)  
 background, 113–14  
 supportive care in unexplained  
 recurrent miscarriage (RM), 124
- thrombophilia (inherited), 131–2  
 and pregnancy failure association,  
 133–5
- antithrombin deficiency, *See*  
 antithrombin deficiency  
 clinical implications in early  
 pregnancy, 135–8
- elevated factor VIII, *See* factor VIII,  
 elevated
- factor V Leiden mutation, *See* factor  
 V Leiden mutation
- protein C deficiency, *See* protein C  
 deficiency
- protein S deficiency, *See* protein S  
 deficiency
- prothrombin mutation, *See*  
 prothrombin mutation
- recurrent implantation failure (RIF)  
 and, 214–15
- venous thromboembolism (VTE)  
 risk in pregnancy, 132–3
- thrombophilia testing, 61–2
- thromboxane A (TXA), 117
- thyroid disease, 60260
- thyroid-stimulating hormone (TSH),  
 175260
- tissue factor (TF)–activated factor VII  
 (FVIIa) complex, 131

## Index

- tissue inhibitors of metalloproteinases (TIMPs), 206  
 transcription factors, 202  
 transcriptional analysis, of embryo, 240  
 transcriptomic analysis, 241  
 transforming growth factor-beta (TGF- $\beta$ ), 7579230  
 travel-related venous thromboembolism (VTE)  
   background information, 143  
   early pregnancy travel advice, 147–8  
   estimating risk of, 146  
   prevention of, 146–7  
   thrombosis risk and pregnancy, 143–4  
   thrombosis risk and travel, 144–6  
 trisomy, *See* chromosomal/cytogenetic abnormality  
 trophoblast invasion, 201–2  
   consequences of failed transformation of spiral arteries, 229–30  
   excessive/inadequate, 208229–30  
   factors affecting, 230–1  
   spiral artery plug formation, 229  
   transformation of spiral arteries, 228–9  
   uterine natural killer (uNK) cell regulation of, 78–9  
 trophoblast membrane infusion, 81  
 trophoblast regression, 35  
 trophoblasts  
   and immunosuppression in implantation, 207  
   deportation of, 231–2  
   genetic abnormality and, 232  
   implantation overview, 227–8  
 trunk defects, embryonic, 107  
 tubal disease  
   ectopic pregnancy and, 20  
   post-IVF miscarriage risk and, 259–60  
   recurrent implantation failure (RIF) and, 213  
 tumour necrosis factor-alpha (TNF- $\alpha$ ), 7579  
 Turner's syndrome, 949  
 twin gestation  
   conjoined twins, 49107–8  
   embryo reduction in, *See* embryo reduction (ER)  
   fetus and mole co-existence, 69–70  
   incipient twins, 268  
   late intrauterine death, 272  
   monochorionic diamniotic (MCDA) or monochorionic monoamniotic (MCMA), 43–4  
   perigestational hemorrhage (PGH) and, 48  
   risks of, 267  
   vanishing twin syndrome, *See* vanishing twin syndrome  
 twin peak sign, 43  
 ultrasound  
   abnormal findings in first-trimester pregnancy, 47–50  
   congenital uterine anomaly detection and diagnosis, 29–33, 280  
   crown-rump length (CRL) measurement, 4043103  
   early pregnancy failure findings, 44–7  
   early pregnancy revised nomenclature and findings, 1–2, 3  
   ectopic pregnancy, 19–20  
   embryo reduction (ER) use, 246–8  
   embryo transfer guidance, 219  
   embryonic circulation Doppler imaging, 228  
   endometrial assessment use, 177–9  
   expected date of delivery (EDD) confirmation, 39–43  
   goals in early pregnancy, 39  
   lower limb thrombus detection, 145  
   mean sac diameter (MSD) measurement, 4043  
   miscarriage classification, 60  
   molar pregnancy, 67–8, 71–2  
   multiple gestation first-trimester findings, 43–4  
   normal early pregnancy findings and milestones, 39–43  
   positive pregnancy test and empty uterus guidelines, 46  
   pregnancy duration assessment criteria, 2–4  
   pregnancy loss classification and findings, 5  
   recurrent implantation failure (RIF) investigation, 216  
   recurrent miscarriage (RM) future pregnancy management, 123  
   sonohysterography, 179–80  
   standards for competence, 4  
   transabdominal or transvaginal in first trimester, 39  
   uterine artery Doppler, 119124  
   179, 229  
   vanishing twin syndrome detection, 267268269–70  
 umbilical cord defects, embryonic, 107  
 unexplained infertility (UI), endometrial assessment in, 183–4  
 unicornuate uterus, 323334–5, *See also* congenital uterine anomalies  
 uniparental disomy (UPD), 94–5  
 uterine agenesis, 33  
 uterine artery Doppler ultrasound  
   endometrial assessment use, 179  
   thrombophilia use, 119124  
   utero-placental vascular impairment detection, 229  
 uterine contractions, as miscarriage symptom, 54  
 uterine dysgerminomas, 69  
 uterine natural killer (uNK) cells, 75–6  
   functions of, 78–9  
   future research directions, 81–2  
   menstruation regulation and, 77–8  
   recurrent implantation failure (RIF) and, 81  
   recurrent miscarriage (RM) and, 6279–81  
   source of, 76–7  
   steroid therapy and, 220  
 uterine polyps, 180  
 uterine vasodilatation, 219–20  
 uterodomes, 176 *See also* pinopodes  
 uterus arcuatus, 280 *See also* congenital uterine anomalies  
 uterus didelphys, 280 *See also* congenital uterine anomalies  
 vaginal bleeding  
   as miscarriage symptom, 53–4  
   in molar pregnancy, 6870  
   vanishing twin syndrome and, 268–9  
 vaginal douching, as ectopic pregnancy risk factor, 20  
 vanishing twin syndrome  
   definition of, 267268  
   diagnosis of, 269–70  
   frequency of, 269–70  
   long-term outcome, 272–3  
   obstetric complications, 270–2  
   pathology of, 267–8  
   vanishing embryo syndrome and, 268–9  
 vascular endothelial growth factors (VEGF), 205–6  
 vascular remodeling regulation, 79  
 vasculogenesis, 228  
 venous thromboembolism (VTE)  
   risk in pregnancy, 132–3, 143–4  
   thrombophilia, *See* thrombophilia (acquired); thrombophilia (inherited)



travel-related, <i>See</i> travel-related venous thromboembolism (VTE)	pre-pregnancy weight and miscarriage risk, 1112	visualization of, 40–1
vitamin intake, miscarriage risk and, 1112	weight loss, 221–2, 259	yolk sac miscarriage, 60
vitamin K antagonists, 136	wellbeing, emotional, 1116	
	window of implantation (WOI), 161167171–3, 176	zona pellucida, 199
warfarin embryopathy, 136		zygote assessment, 238–9
weight		zygote intra-fallopian transfer (ZIFT), 240
obesity, <i>See</i> obesity	yolk sac	zygotic genome activation, 199
	abnormal ultrasound findings, 47	